474 related articles for article (PubMed ID: 28695059)
1. B7-H3 role in the immune landscape of cancer.
Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
[TBL] [Abstract][Full Text] [Related]
2. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
Shao L; He Q; Wang J; He F; Lin S; Wu L; Gao Y; Ma W; Dong J; Yang X; Li F
Cell Death Discov; 2021 Jun; 7(1):145. PubMed ID: 34131111
[TBL] [Abstract][Full Text] [Related]
6. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
7. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
8. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of the Expression of Co-Stimulatory Molecule B7-H3 in Papillary Thyroid Carcinoma.
Zhao B; Huang Z; Zhu X; Cai H; Huang Y; Zhang X; Zhang Z; Lu H; An C; Niu L; Li Z
Front Cell Dev Biol; 2022; 10():819236. PubMed ID: 35493085
[No Abstract] [Full Text] [Related]
10. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Leung J; Suh WK
Immune Netw; 2014 Dec; 14(6):265-76. PubMed ID: 25550693
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
12. B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.
Rasic P; Jovanovic-Tucovic M; Jeremic M; Djuricic SM; Vasiljevic ZV; Milickovic M; Savic D
World J Gastrointest Oncol; 2021 Aug; 13(8):799-821. PubMed ID: 34457187
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 Immune Checkpoint Protein in Human Cancer.
Flem-Karlsen K; Fodstad Ø; Nunes-Xavier CE
Curr Med Chem; 2020; 27(24):4062-4086. PubMed ID: 31099317
[TBL] [Abstract][Full Text] [Related]
17. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
18. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
19. B7-H3/CD276 and small-cell lung cancer: What's new?
Fabrizio FP; Muscarella LA; Rossi A
Transl Oncol; 2024 Jan; 39():101801. PubMed ID: 37865049
[TBL] [Abstract][Full Text] [Related]
20. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
